RxDoctor Payments DataLook up a doctor →

Derek Smith, MD

Neurology · Norwich, CTNPI 1407869019

Payments from drug & device makers

$560,653in general payments, 2019–2025

Across 1,784 payments — averaging $314.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$163K
  • EMD Serono, Inc.$83K
  • TG Therapeutics, Inc.$80K
  • Sanofi$41K
  • E.r. Squibb & Sons, L.L.C.$41K
  • Roche Products Limited$34K
  • plus $119K from 54 others

What the payments were for

  • Consulting fees$93,96920%
  • Speaking & faculty fees$310,47866%
  • Travel & lodging$22,4275%
  • Food & beverage$41,8299%
  • Education$2860%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen230$163,316
EMD Serono, Inc.196$83,053
TG Therapeutics, Inc.76$80,253
Sanofi52$40,932
E.r. Squibb & Sons, L.L.C.44$40,658
Roche Products Limited58$33,575
Genentech USA, Inc.94$31,719
Novartis158$30,901
Bristol Myers Squibb101$24,164
Johnson & Johnson32$11,846
AbbVie(2 entities)192$3,953
Genentech, Inc.10$2,894
Amgen(2 entities)61$1,750
Pfizer69$1,354
Sunovion Pharmaceuticals Inc.79$1,054
Teva Pharmaceuticals USA, Inc.35$774
UCB, Inc.23$720
Otsuka America Pharmaceutical, Inc.13$534
Lundbeck LLC15$516
Amneal Pharmaceuticals LLC22$510
Argenx US, Inc.7$468
Mallinckrodt Hospital Products Inc.18$380
Sumitomo Pharma America, Inc.25$376
Eisai Inc.11$368
Axsome Therapeutics, Inc.9$353
Biohaven Pharmaceutical Holding Company Ltd.17$352
Biohaven Pharmaceuticals, Inc.21$344
Vanda Pharmaceuticals Inc.5$330
Avanir Pharmaceuticals, Inc.16$298
Abbott2$263
Neurocrine Biosciences, Inc.2$247
ANI Pharmaceuticals, Inc.6$239
AstraZeneca(2 entities)11$226
Lilly USA, LLC7$220
Cycle Pharmaceuticals Inc5$181
CSL Behring9$172
Ipsen Biopharmaceuticals, Inc2$140
SK Life Science, Inc.5$127
Alnylam Pharmaceuticals Inc.1$125
Alkermes, Inc.1$124
Currax Pharmaceuticals LLC6$89
Mallinckrodt Enterprises LLC4$89
Grifols USA, LLC4$79
Takeda Pharmaceuticals U.S.A., Inc.3$58
Supernus Pharmaceuticals, Inc.2$51
Octapharma USA, Inc.2$50
Upsher-smith Laboratories LLC3$45
Life Molecular Imaging Ltd2$40
Jazz Pharmaceuticals Inc.2$39
Tanabe Pharma America, Inc.2$38
Scilex Pharmaceuticals Inc.2$36
Almatica Pharma LLC2$34
GE HealthCare1$30
Assertio Therapeutics, Inc.2$29
Convatec Inc.1$27
Averitas Pharma Inc.1$24
Banner Life Sciences, LLC1$21
Sanofi-aventis U.S. LLC1$19
Acorda Therapeutics, Inc1$18
Kyowa Kirin, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$560,653 in reported general payments places this provider in the 90th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$34,694
Medicare patients
183
Services billed
21,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcrevusOcrelizumab32$1,343,353
TysabriNatalizumab78$688,952
Kesimpta PenOfatumumab46$399,226
TecfideraDimethyl Fumarate36$386,249
FingolimodFingolimod Hcl77$359,187
Dimethyl Fumarate66$150,558
MayzentSiponimod17$146,552
GilenyaFingolimod Hcl12$128,015
CopaxoneGlatiramer Acetate18$121,067
Nurtec OdtRimegepant Sulfate74$97,068
VumerityDiroximel Fumarate11$95,450
Glatiramer Acetate48$87,930
Teriflunomide27$78,279
NuedextaDextromethorphan Hbr/Quinidine44$73,390
Aimovig AutoinjectorErenumab-Aooe32$34,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Ocrevus$2,894$1,343,35332 claims
BiogenTysabri, Tecfidera, Vumerity$163,316$1,170,651125 claims
NovartisMayzent, Gilenya$30,901$274,56729 claims
Teva Pharmaceuticals USA, Inc.Copaxone$774$121,06718 claims
PfizerNurtec Odt$1,354$97,06874 claims
Avanir Pharmaceuticals, Inc.Nuedexta$298$73,39044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 280 neurology providers in Connecticut.

Other neurology in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →